戻る Agenda
Poster Session 3 – Clinical Development & Value and Access
Session Chair(s)
Sara Torgal, MPharm
Global Regulatory Policy Lead
DIA, Switzerland
Poster authors will present their poster in a short pitch format, followed by a moderated Q&A.
Learning Objective : Brain metastases (BM) occur in ~30-50% of ALK+ NSCLC patients, and are associated with poor outcomes. The response assessment of BM (Brain metastases) is challenge given the complexity of RANO and its unknown concordance with RECIST1.1, and we conducted a study to assess their concordance.
Speaker(s)
Modified RECIST1.1 vs RANO HGG in assessing the intracranial efficacy of ceritinib in pts with brain metastases in ALK+ NSCLC
Yingbo Wang, MD, PhD
Novartis, Switzerland
Associate clinical development medical director
A Global Rheumatoid Arthritis Trial Involving Biologic vs. Biosimilar: The Medical Affairs and Clinical Operations Challenges
Nermina Nakas, MD, MPH
Syneos Health, United States
Vice President, Medical & Scientific Strategy
Generating Disease Insights on Patient Journey, Treatments and Outcomes by Use of Global Hospital Network EHR
Douglas Drake, MBA
LOGEX, Switzerland
Digital Health Strategy
Predicting Patient-Reported Outcomes After Hip and Knee Replacement Surgeries: Examples in Super Learning
Maciej Maruszczak, MSc
Parexel, United Kingdom
Consultant in Data Analytics and Machine Learning
Are Health Systems Ready for Assessing the Value and Funding Digital Health Solutions?
Camille Andre, PharmD
Roche, Switzerland
Health System Strategy Leader